Evaluation of the impact of 13-valent pneumococcal conjugate vaccine immunization in children by surveillance of culture-confirmed pneumococcal disease: a …

CH Chen, LH Su, HC Li, MH Hsu, TL Wu, CL Chen… - Vaccine, 2019 - Elsevier
The study aimed to investigate the impact of 13-valent pneumococcal conjugate vaccine
(PCV13) immunization on the overall pneumococcal disease in children in Taiwan by …

Impact of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease after introduction into routine pediatric use

R Baxter, L Aukes, SI Pelton, A Yee… - Journal of the …, 2021 - academic.oup.com
Abstract Background In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13)
replaced 7-valent PCV (PCV7) for protection against invasive pneumococcal disease (IPD) …

Redistribution of Streptococcus pneumoniae serotypes after Nationwide 13-valent pneumococcal conjugate vaccine program in children in northern Taiwan

YC Cho, NC Chiu, CY Lu, DTN Huang… - The Pediatric …, 2017 - journals.lww.com
Background: After the introduction of 13-valent pneumococcal conjugate vaccine (PCV13)
against Streptococcus pneumoniae, public health officials in Taiwan monitored a decline in …

[HTML][HTML] Impact of pneumococcal conjugate vaccine in children on the serotypic epidemiology of adult invasive pneumococcal diseases in Taiwan

HC Chi, YC Hsieh, MH Tsai, CH Lee, KC Kuo… - Journal of microbiology …, 2018 - Elsevier
Background Invasive pneumococcal disease (IPD) causes significant morbidity and
mortality, especially in children and older adults. Pneumococcal 7-valent and 13-valent …

[HTML][HTML] Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules

HY Lee, YC Hsieh, CC Liu, YC Huang… - Journal of microbiology …, 2018 - Elsevier
Abstract Background In Taiwan, the age group with the greatest incidence of invasive
pneumococcal disease is 2–5 years of age, which is different from other countries. This …

Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta

J Leal, OG Vanderkooi, DL Church… - The Pediatric …, 2012 - journals.lww.com
Background: The seven-valent pneumococcal conjugate vaccine (PCV7) was licensed in
Canada in 2001. Routine infant vaccination programs in Alberta began in 2002. Several …

Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine

SL Kaplan, WJ Barson, PL Lin, JR Romero… - The Pediatric …, 2013 - journals.lww.com
Background: The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced for
routine administration to infants and children in 2010 in the United States. We have …

Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults

RA Gladstone, JM Jefferies, SN Faust… - Expert review of …, 2012 - Taylor & Francis
Pneumococcal disease remains a global problem despite the availability of effective
conjugate vaccines. The 13-valent pneumococcal conjugate vaccine (PCV13) extends the …

Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine

S Tomczyk, R Lynfield, W Schaffner… - Clinical Infectious …, 2016 - academic.oup.com
Background. Antibiotic-nonsusceptible invasive pneumococcal disease (IPD) decreased
substantially after the US introduction of the pediatric 7-valent pneumococcal conjugate …

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite …

MR Moore, R Link-Gelles, W Schaffner… - The Lancet Infectious …, 2015 - thelancet.com
Background In 2000, seven-valent pneumococcal conjugate vaccine (PCV7) was introduced
in the USA and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and …